Skip to content
10-K

Annual Report

ARS Pharmaceuticals, Inc. SPRY

0000950170-25-042320

← back to feed
Filed
Mar 20, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 17, 2025 98.12M sh
Shares Diluted FY 2024 · Dec 31, 2023 95.22M sh
Capex FY 2024 · Dec 31, 2023 $175K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$59.27M
Short Term Investments FY 2024 · Dec 31, 2023 $157.39M
Cash And Equivalents FY 2024 · Dec 31, 2023 $70.97M
Current Liabilities FY 2024 · Dec 31, 2023 $2.39M
Total Liabilities FY 2024 · Dec 31, 2023 $2.43M
Current Assets FY 2024 · Dec 31, 2023 $231.73M
Total Assets FY 2024 · Dec 31, 2023 $233.19M
Eps Diluted FY 2024 · Dec 31, 2023 −$0.57
Eps Basic FY 2024 · Dec 31, 2023 −$0.57
Sga Expense restated FY 2024 · Dec 31, 2023 $47.28M
Rd Expense FY 2024 · Dec 31, 2023 $20.27M
Net Income FY 2024 · Dec 31, 2023 −$54.37M
Operating Income FY 2024 · Dec 31, 2023 −$67.52M
Cost Of Revenue FY 2024 · Dec 31, 2023 $0
Revenue FY 2024 · Dec 31, 2023 $30K
Stockholders Equity FY 2024 · Dec 31, 2022 $272.89M